# Study Evaluating ERB-041 in Active Crohn's Disease

> **NCT00245947** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** ERB-041

## Key facts

- **NCT ID:** NCT00245947
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2009-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245947, "Study Evaluating ERB-041 in Active Crohn's Disease". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00245947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*